

Cover Story

Industry Audit

Bill Trombetta

St. Joseph's University

Running the numbers on pharma: 16 top companies, 23 essential business metrics. Plus: the companies of the year.

72

“How the mighty have fallen. In 2002, pharma had three of the top 10 corporate profit makers: Pfizer, Merck, and J&J. But in 2003, not a single pharma company placed among the top 10.”



Features

Business Models

Out of the Mouths of Babes

Mason Tenaglia

Charles River Associates

What will Medicare reform do to pharma? Look what WIC did to infant formula.

48

Market Research

Putting the Data to Work

A Pharm Exec forum

A panel of industry experts addresses the question: Now that you're drowning in customer data, what can you do with the information?

114

E-Pedigree

Safe and Secure

Lew Kontnik

Lew Kontnik Associates

Shabbir Dahod

SupplyScape, Inc.

Mass serialization and RFID are pharma's greatest hopes. Here's what has to happen for them to work.

58

Regulatory

Halting the Hype

Leigh-Ann Patterson

Nixon Peabody LLP

In the wake of the ImClone scandal, FDA and SEC are working together to crack down on misleading promotional statements.

126

Cutting Edge

Synta's Surprise

L.J. Sellers

Senior Editor

Here's a twist: The big pharmas developed the protein. Now a biotech is following up with the small molecule.

92

R&D

Building Blocks for Blockbusters

Jan Malek

PA Consulting

Big-selling drugs aren't a thing of the past. They just require new strategies. Here are three key ones.

134

Marketing

Spend Trends

Michael D. Lam

Associate Editor

Detailing, DTC, and beyond. How the industry allocates its \$20 billion marketing budget.

100

Managed Care

Specialty Therapies Lose Special Status

Thomas Baker

The Zitter Group

Managed care is revamping the way it pays for biologics. Guess who's supposed to pay for the next round of savings.

142

News & Analysis

Leading Indicators

News

What's driving healthcare costs? » Greenwood to head BIO » NIH backs Abbott on Norvir » Phase IV studies on the rise » Endo licenses migraine drug » Bayer buys Roche consumer division » Looking for the tipping point

I 7

Data

OTC statins » Measuring "internet relevance" » How consumers feel about Medicare reform

2 8

Thought Leaders

Entelos' Mikhail Gishizky says biosimulation could help predict the outcome of head-to-head trials.

3 2

Washington Report

CMS's new Medicare regulations cover a lot of ground. Here's what they leave out.

Jill Wechsler

3 6

Global Report

As animal-rights activists turn their focus to a new Oxford lab, the government takes a tougher stand.

Sarah Houlton

4 0

Leadership

Donald Trump has it right: Apprenticeship is an ideal model for training leaders.

Sander A. Flaum

Flaum Partners

4 2

Toolkit

Now that you've outsourced staffing, maybe you should think about outsourcing your outsourcing.

Andrew Schultz

PrO Unlimited

4 6

Strategy & Tactics

Direct to Consumer

Leverage your pre-launch promotional investment by using corporate branding throughout the product lifecycle.

Ken DeLor

The DeLor Group

I 4 9

Marketing to Professionals

Health literacy requires tactical practice. Reps can help.

Jann Keenan

The Keenan Group

I 5 4

Sales Management

More reps do count—just not on the bottom line.

James Callandrillo

NOF

I 6 8

Alternative Media

After Zolof's debut in *The Sixth Sense*, pharma companies wonder if product placement is right for them. A Q&A with the Sterling Group's Simon Williams.

I 5 8

Public Relations

The request for proposal process is a nightmare. But it's easy to make it more effective.

Kathy Cripps

The Council of PR Firms

I 6 4

Insights

From the Editor

The debate over pricing is important. But why does it have to be so boring?

Patrick Clinton

Editor-in-Chief

I 4

Back Page

FDA needs more scientific ways to measure such vagaries as fair balance.

Peter Pitts

Manning, Selvage & Lee

I 8 6

Resources

People Update

I 7 4

Calendar of Events

I 7 8

Contacts

I 8 2

Advertisers Index

I 8 4